Approval · Notice of Compliance 25268 · 2021
INFLECTRA: Notice of Compliance 25268
Issued February 19, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25268
- Date
- February 19, 2021
- Company
- Celltrion Healthcare Co Ltd
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New drug product manufacturing site
- Canadian reference product
- REMICADE
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| INFLECTRA | Not yet assigned | — |
Medicinal ingredients
- INFLIXIMAB 100 MG per VIAL